IMUGENE LIMITED — Capital/Financing Update 2023

Aug 24, 2023

==> picture [177 x 31] intentionally omitted <==

ASX Announcement

Placement and Share Purchase Plan update

Not for release to US wire services or distribution in the United States

SYDNEY, Australia, Friday, 25 August 2023: Imugene Limited (ASX:IMU) ( Company ), refers to the ASX announcement "Imugene Completes Strongly Supported $35M Placement & Launches ~$30M SPP" made on 18 August 2023 and is pleased to provide an update on the current Placement and Share Purchase Plan ( SPP ).

Placement

The Company confirms that it has today allotted 411.2 million fully paid ordinary shares at an issue price of $0.084 to Placement Subscribers (other than Directors). An application has been made to ASX for quotation of the Placement Shares, per the Appendix 2A lodged today.

SPP

As announced on 18 August 2023, the follow on SPP to raise approximately $30 million will open on Monday, 28 August 2023 ( Opening Date ). Notwithstanding this target raise amount, the Company reserves its right to accept more or scale back applications under the SPP.

The SPP and the offer of New Options to Placement Subscribers and Eligible Shareholders is set out in a prospectus ( Prospectus ), which has been lodged both with ASIC and ASX today, and is also available on the Company's website at www.imugene.com/announcements

New Options and Placement Shares subject to shareholder approval

The issuance of the New Options and Placement Shares to Directors will be subject to shareholder approval at an extraordinary general meeting ( EGM ) to be convened at the end of September 2023. The notice of meeting for the EGM will be despatched to shareholders shortly.

IMUGENE LIMITED ACN 009 179 551 WWW.IMUGENE.COM info@imugene.com

==> picture [42 x 42] intentionally omitted <==

Key Dates

Event	Date
Allotment of New Shares issued under the Placement (other than to Directors)	Friday, 25 August 2023
Prospectus date	Friday, 25 August 2023
Despatch of Prospectus	Monday, 28 August 2023
Opening Date of SPP and Options Offer	Monday, 28 August 2023
Closing Date for SPP and Options Offer	Thursday, 14 September 2023
Allotment of New Shares under the SPP	Tuesday, 19 September 2023
Despatch of Holding Statements for New Shares under SPP	Wednesday, 20 September 2023
Normal ASX trading for New Shares issued under the SPP commences	Wednesday, 20 September 2023
Extraordinary general meeting to approve issuance of New Options and Directors’ participation in the Placement	End of September 2023
Issuance of New Options and Placement Shares to Directors (subject to shareholder approval having been obtained)	End of September 2023

Enquiries

From Friday, 25 August 2023, a copy of the Prospectus will be available via the Company’s website at www.imugene.com (without Application Forms) or can be obtained by contacting the Company’s Share Registry on the number noted below.

IMUGENE LIMITED ACN 009 179 551

2

==> picture [42 x 42] intentionally omitted <==

For further information relating to the Offer, please contact the Company’s Share Registry, Automic Registry Service Limited, on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia), at any time between 8:30am and 5:30pm (AEST), Monday to Friday (excluding public holidays) until the closing date of the SPP and Options Offer.

For more information please contact:

Leslie Chong Managing Director and Chief Executive Officer

info@imugene.com

Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene Like us on Facebook @Imugene Connect with us on LinkedIn @Imugene Limited Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer, multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team

IMUGENE LIMITED ACN 009 179 551

3

==> picture [42 x 42] intentionally omitted <==

of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements under the US Securities Act and applicable US state securities laws.

Forward-looking statements

This announcement contains certain ‘forward-looking statements’ within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as ‘may,’ ‘should,’ ‘expect,’ ‘anticipate,’ ‘estimate,’ ‘scheduled’ or ‘continue’ or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Imugene does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

IMUGENE LIMITED ACN 009 179 551

4